In the Bubble with Andy Slavitt cover image

Are We on the Verge of Curing Alzheimer’s?

In the Bubble with Andy Slavitt

00:00

Adicannemap - What's Controversy?

Adicannemap is an antibody that attacks amyloid deposits in brain. FDA and Medicare had to make a decision on whether the drug should be approved. Adjelm has caused some controversy, but it's not clear if there are any problems with its safety or effectiveness.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app